NYSE:DOCSHealthcare Services
AI Disruption Jitters and Insider Sales Might Change The Case For Investing In Doximity (DOCS)
In recent days, Doximity has been in focus as investors, analysts, and fund managers reassessed the company’s prospects amid new AI innovations and insider Form 144 stock sale filings tied to option exercises.
What stands out is that, even as AI tools like Anthropic’s Managed Agents spark concern about disruption to traditional SaaS models, several investors still frame Doximity as a potential long-term beneficiary of AI given its physician-centric platform and existing AI product...